Mark D Pegram

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

Jungsil Ro, J. Baselga, S. Verma, 2016, Clinical Cancer Research.

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Molly Brewer, Beth Y Karlan, Daniela Matei, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Anthony Rhodes, Lisa M McShane, Soonmyung Paik, 2006, Archives of pathology & laboratory medicine.

Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.

G. Konecny, M. Pegram, Mark D Pegram, 2004, Oncology.

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

R. Finn, D. Slamon, M. Pegram, 1998, Oncogene.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Anthony Rhodes, Lisa M McShane, Soonmyung Paik, 2007, Archives of pathology & laboratory medicine.

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

M. Berger, M. Untch, R. Finn, 2006, Cancer research.

Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.

Michael E Phelps, Wei-Ann Hsueh, Betty S Pio, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.